Oral Subchronic Toxicity of a Lipid Extract from Roystonea regia Fruits in Mice

REFERENCES

• Alemán C. L., Noa M., Más R., Rodeiro I., Mesa R., Menéndez R., Gámez R., Hernández C. Reference database for the principal physiological indicators in three species of laboratory animals. Lab Animals 2000; 34: 379–385
   PubMed Web of Science ®Google Scholar
• Aliev I. G., Vinarov A. Z., Lokshin K. L., Spivak L. G. Five-years experience in treating with prostatic hyperplasia patients with permixon (Serenoa repens Pierre Fabre Medicament). Urologia 2002; 1: 23–25
   Google Scholar
• Andress J. M., Frith C. H., Goodman D. G., Boysen B. G., Cook C. S. The mouse. Animal Models in Toxicology, S.C. Gad, C.P. Chengelis. Marcel Dekker, New York 1992; 165–294
   Google Scholar
• Arruzazabala M. L., Carbajal D., Más R., Molina V., González V., Rodríguez E. Preventive effects of D-004, a lipid extract from Cuban royal palm (Roystonea regia) fruits, on prostate hyperplasia induced with testosterone on intact and castrated rodents. Drugs Exp. Clin. Res. 2004; 30: 227–234
   PubMedGoogle Scholar
• Arruzazabala M. L., Más R., Carvajal D., Molina V. Effect of D-004, a lipid extract from Cuban royal palm fruit, on in vitro and in vivo effects mediated by α adrenoceptors in rat. Drugs R & D 2005; 6: 281–289
   PubMedGoogle Scholar
• Arruzazabala M. L., Más R., Molina V., Noa M., Carvajal D., Mendoza N. Effect of D-004, a lipid extract from the Cuban royal palm fruit on atypical prostate hyperplasia induced by phenylephrine in rats. Drugs R & D 2006; 7: 233–241
   PubMedGoogle Scholar
• Bartsch G., Rittmaster R. S., Klocker H. Dihydrotestosterone and the concept of 5 alpha reductase inhibition in human benign prostatic hyperplasia. Eur. Urol. 2000; 37: 367–380
   PubMed Web of Science ®Google Scholar
• Bartsch G., Rittmaster R. S., Klocker H. Dihydrotestosterone and the role of 5 alpha-reductase inhibitors in benign prostatic hyperplasia. Urologe A 2002; 41: 412–424
   PubMedGoogle Scholar
• Bhargava S., Canda A. E., Chapple C. R. A rational approach to benign prostatic hyperplasia evaluation: recent advances. Curr. Opin. Urol. 2004; 14: 1–6
   PubMed Web of Science ®Google Scholar
• Carbajal D., Arruzazabala M. L., Mas R., Molina V., Rodríguez E., González V. Effect of D-004, a lipid extract from Cuban royal palm fruit, on inhibiting prostate hyperplasia induced with testosterone and dihydrotestosterone in rats. Curr. Ther. Res. Clin. Expt. 2004; 65: 505–514
   PubMed Web of Science ®Google Scholar
• Carbajal D., Molina V., Más R., Arruzazabala M. L. Therapeutic effect of D-004, a lipid extract from Roystonea regia fruits, on prostate hyperplasia induced in rats. Drugs Exp. Clin. Res. 2005; 31: 193–198
   PubMedGoogle Scholar
• Carraro J. C., Raynaud J. P., Koch G., Chisholm G. D., Di Silverio F., Teillac P., Da Silva F. C., Cauquil J., Chopin D. K., Hamdy F. C., Hanus M., Hauri D., Kalinteris A., Marencak J., Perier A., Perrin P. Comparison of phytotherapy (Permixon) with Finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1098 patients. Prostate 1996; 29: 231–240
   PubMed Web of Science ®Google Scholar
• Carson C., Rittmaster R. The role of dihydrotestosterone in benign prostatic hyperplasia. Urology 2003; 61: 2–7
   PubMed Web of Science ®Google Scholar
• Chhabra R. S., Huff J. E., Schwetz B. S., Selkirk J. An overview of prechronic and chronic toxicity/carcinogenicity experimental study designs and criteria used by the National Toxicology Program. Environ. Health Perspect. 1990; 86: 313–321
   PubMed Web of Science ®Google Scholar
• Debruyne F., Koch G., Boyle P., Da Silva F. C., Gillenwater J. G., Hamdy F. C., Perrin P., Teillac P., Vela-Navarrete R., Raynaud J. P., for Groupe d'etude PERMAL. Comparison of phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: 1-year randomized international study. Prog. Urol. 2002; 2: 384–392
   Google Scholar
• Dorato M. A., Voracnik M. The toxicology assessment of pharmaceutical and biotechnology products. Principles and Methods of Toxicology, A. W. Hayes. Raven Press, New York 1994; 189–219
   Google Scholar
• Gámez R., Mas R., Noa M., Menéndez R., García H., Rodríguez Y., Rodríguez Y., Felipe E., Goicochea E. Oral acute and subchronic toxicity of D-004, a lipid extract from Roystonea regia fruits, in rats. Drugs Exp. Clin. Res. 2005; 31: 101–108
   PubMedGoogle Scholar
• Gong E. M., Gerber G. S. Saw palmetto and benign prostatic hyperplasia. Am. J. Chin. Med. 2004; 32: 331–318
   PubMed Web of Science ®Google Scholar
• Gormley G. J., Stoner E., Bruskewitz R. C. The effect of finasteride in men with benign prostatic hyperplasia. N. Engl. J. Med. 1992; 327: 1185–1191
   PubMed Web of Science ®Google Scholar
• Hall R. Clinical pathology of laboratory animals. Product Safety Evaluation Handbook, S.C. Gad, C. P. Chengelis. Marcel Dekker, New York 1999; 765–811
   Google Scholar
• Lee P. N. Statistics. Experimental Toxicology, the Basic Issues, D. Anderson. BIBRA, New YorkSurrey, United Kingdom 1993; 405–411
   Google Scholar
• Long G., Symanowski T., Roback K. Precision in data acquisition and reporting of organ weights in rats and mice. Toxicol. Pathol. 1998; 26: 316–318
   PubMed Web of Science ®Google Scholar
• Lowe F. C., Dreikorn K., Borkowski A., Braeckman J., Denis L., Ferrari P., Gerber G., Levin R., Perrin P., Senge T. Review of recent placebo-controlled trials utilizing phytotherapeutic agents for treatment of BPH. Prostate 1998; 37: 187–193
   PubMed Web of Science ®Google Scholar
• Matsuzawa T., Nombra M., Unno T. Clinical pathology references ranges of laboratory animals. J. Vet. Med. Sci. 1993; 55: 351–362
   PubMed Web of Science ®Google Scholar
• American Herbal Product Association's Botanical Safety Handbook, M. McGuffin, C. Hobbs, R. Upton, A. Goldberg. CRC Press, Boca Raton, FloridaUSA 1997; 107
   Google Scholar
• Michel M. C., Taguchi K., Schafers R. S., Williams T. J., Clarke D. E., Ford A. P. Alpha 1-adrenoceptor subtypes in the human cardiovascular and urogenital systems. Adv. Pharmacol. 1998; 42: 394–398
   PubMedGoogle Scholar
• Noa M., Arruzazabala M. L., Carbajal D., Más R., Molina V. Effect of D-004, a lipid extract from Cuban royal palm fruit, on histological changes of prostate hyperplasia induced with testosterone in rats. Int. J. Tissue Reac. 2005; 27: 203–211
   PubMedGoogle Scholar
• Olke M., Hofner K., Berges R. R., Jonas U. Drug therapy of benign prostatic hyperplasia syndrome with alpha 1-receptors blockers. Basic principles and clinical results. Urologe A 2002; 41: 425–441
   PubMedGoogle Scholar
• Pérez Y., Menéndez R., Mas R., González R. Efecto in vitro del D-004, extracto lipídico de los frutos de la palma real, sobre receptores androgénicos de tejido prostático (In vitro effect of D-004. A lipid extract from the Cuban Royal Palm (Roystinea regia) fruits, prostastic and rogenic receptors. Rev. CENIC Cien. Biol. 2006a; 38: 23–25
   Google Scholar
• Pérez Y., Menéndez R., Mas R., González R. In vitro effect of D-004, a lipid extract from the Cuban Royal palm (Roystonea regia) fruits, on the activity of prostate steroid 5-alpha reductase. Curr. Ther. Res. Clin. Exptl. 2006b; 67: 396–405
   PubMed Web of Science ®Google Scholar
• Pérez Y., Menéndez R., Mas R., González R. Study of plasma levels, tissue distribution, and excretion of radioactivity after single oral administration of D-004, a lipid extract of Roystonea regia fruit, supplemented with 3H-oleic acid. Curr. Ther. Res. Clin. Exptl. 2006c; 67: 406–412
   PubMed Web of Science ®Google Scholar
• Piccirillo V. J. Repeated-dose toxicity studies. Product Safety Evaluation Handbook, S. C. Gad. Marcel Dekker, New York 1999; 201–202
   Google Scholar
• Plosker G. L., Brogden R. N. Serenoa repens (Permixon). A review of its pharmacology and therapeutic efficacy in benign prostate hyperplasia. Drugs Aging 1996; 9: 379–395
   PubMed Web of Science ®Google Scholar
• Sandhu J. S., Te A. E. The role of 5 alpha-reductase inhibition as monotherapy in view of the MTOPS data. Curr. Urol. Rep. 2004; 5: 274–279
   PubMedGoogle Scholar
• Simpson R. J. Benign prostatic hyperplasia. An overview of epidemiology and treatment. Primary Care N. H. S. 2001; 184–186
   Google Scholar
• Tarter T. H., Vaughan E. D., Jr. Inhibitors of 5-alpha-reductase in the treatment of benign prostatic hyperplasia. Curr. Pharm. Des. 2006; 12: 775–783
   PubMed Web of Science ®Google Scholar
• Thorpe A., Neal D. Benign prostatic hyperplasia. Lancet 2003; 19: 1359–1367
   Google Scholar
• Wilt T., Ishani A., MacDonald R. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst. Rev. 2000; 3: CD001523
   Google Scholar
• Wolford S. T., Schorer R. A., Gohs F. X., Gallo P. P., Brodeck M., Falk H. B., Ruhren R. Reference database for serum chemistry and haematology values in laboratory animals. J. Toxicol. Environ. Health 1986; 18: 161–188
   PubMed Web of Science ®Google Scholar